What is the current position of Positron Emission Tomography Computed Tomography (PET CT) in the workup for Pyrexia of Unknown Origin (PUO)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Role of PET/CT in Workup for Pyrexia of Unknown Origin (PUO)

[18F]FDG PET/CT should be considered a valuable second-line investigation in the diagnostic workup of PUO after standard initial evaluations have failed to identify the cause, with a high diagnostic yield of 56% and sensitivity of 84%. 1, 2

Diagnostic Performance of PET/CT in PUO

  • Sensitivity: 84% (79-89%)
  • Specificity: 62% (49-75%)
  • Diagnostic yield: 56% (50-61%)
  • Diagnostic accuracy: 76%
  • Positive predictive value: 67-84.1%
  • Negative predictive value: 80.9-100% 1, 2

The high negative predictive value is particularly valuable as it essentially rules out focal pathology as the cause of fever when negative.

Indications for PET/CT in PUO

Strongly Recommended:

  • PUO without a diagnosis despite standard workup 1
  • Cases where conventional imaging is negative or inconclusive 2
  • Patients with elevated inflammatory markers (CRP, ESR) 1

Insufficient Evidence:

  • Evaluation of patients with PUO and normal inflammatory markers 1

Optimal Timing and Protocol

  • PET/CT should ideally be performed within 3 days of initiation of oral glucocorticoid therapy to avoid false negatives 1
  • Consider myocardial suppression preparation when cardiac etiology is suspected 1
  • Early implementation in the diagnostic workup may improve outcomes by allowing timelier diagnosis 2

Clinical Impact

PET/CT has demonstrated significant clinical impact in PUO management:

  • Guides further investigations and biopsy when positive 1
  • Directs specific treatment when the cause is established 1
  • Predicts favorable prognosis through spontaneous remission when negative 1
  • Leads to treatment modifications in approximately 53% of cases 2
  • Cost-effective, particularly when performed early in the diagnostic workup 1

Common Diagnoses Identified by PET/CT in PUO

  • Infectious causes (including pneumonia, abscesses)
  • Malignancies (particularly lymphomas)
  • Non-infectious inflammatory diseases (vasculitis, particularly aortoarteritis) 3
  • Endocarditis (11%)
  • Systemic juvenile idiopathic arthritis (5%)
  • Inflammatory bowel disease (5%) 2

Advantages Over Other Imaging Modalities

  • Wider diagnostic spectrum compared to labeled white blood cell scans 4
  • Higher sensitivity compared to gallium-67 citrate scanning 4
  • PET/CT technology improves specificity over PET alone 4

Potential Pitfalls and Limitations

False Positives:

  • Recent surgical procedures
  • Foreign body reactions
  • Inadequate suppression of myocardial FDG uptake
  • Physiological uptake in certain organs 2

False Negatives:

  • Prior extended antibiotic therapy
  • Small or mobile lesions
  • Systemic diseases without focal manifestations 2
  • Physiologic excretion of FDG in the urinary tract may interfere with detection of renal infections 5

Practical Recommendations

  1. Use PET/CT as a second-line investigation after initial standard workup fails to identify the cause of PUO 1, 3
  2. Particularly consider PET/CT in suspected non-infectious inflammatory disorders 3
  3. A negative PET/CT scan has excellent negative predictive value and can help rule out focal pathology 6
  4. For suspected renal infections, use diuretics and delayed imaging to improve detection 5
  5. PET/CT is especially valuable in evaluating patients with suspected focal infection or inflammation with a positive predictive value of 95% 7

The latest evidence from the 2025 EANM/SNMMI guideline strongly supports the use of [18F]FDG PET/CT in the diagnostic workup of PUO, particularly after standard initial evaluations have failed to identify the cause 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Diagnostic Imaging for Pyrexia of Unknown Origin (PUO)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Diagnostic utility of fluorodeoxyglucose positron emission tomography/computed tomography in pyrexia of unknown origin.

Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India, 2015

Research

18F-FDG PET and PET/CT in fever of unknown origin.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2007

Research

Localization of acute pyelonephritis in pyrexia of unknown origin using FDG PET/CT.

Asia Oceania journal of nuclear medicine & biology, 2020

Research

Fever of unknown origin: the role of 18F-FDG PET/CT.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.